We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

FUJIREBIO

Fujirebio is a global leader in the field of IVD testing with more than 50 years’ experience in the conception, devel... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Immunoassays Compared for Serum HE4 Estimation for Ovarian Cancer

By LabMedica International staff writers
Posted on 26 Jul 2021
Print article
Image: The HE4 EIA is an enzyme immunometric assay for the quantitative determination of human epididymis protein 4 (HE4) in human serum. HE4 is consistently expressed in patients with ovarian cancer, and it has demonstrated increased sensitivity and specificity over that of CA125 alone (Photo courtesy of Fujirebio)
Image: The HE4 EIA is an enzyme immunometric assay for the quantitative determination of human epididymis protein 4 (HE4) in human serum. HE4 is consistently expressed in patients with ovarian cancer, and it has demonstrated increased sensitivity and specificity over that of CA125 alone (Photo courtesy of Fujirebio)
Ovarian cancer is the sixth most common cancer in women and the leading cause of death from gynecological malignancy in the UK. Cancer antigen 125 (CA125) is the most widely used diagnostic biomarker for ovarian cancer; however it lacks the diagnostic accuracy to reliably detect ovarian cancer at an early stage.

There has been growing interest in human epididymis protein 4 (HE4), a protein found on cells that line the lungs and reproductive organs, such as the ovaries, as an additional serum biomarker for ovarian cancer. With clinical use of HE4 expanding, a high throughput automated assay that allows multiple samples to be analyzed rapidly is needed.

Medical Scientists at the Manchester Academic Health Science Centre (Manchester UK) and their colleagues compared two immunoassay methods for the measurement of serum HE4. The study population included all primary care requested serum CA125 samples received by the Manchester University NHS Foundation Trust (MFT) Clinical Biochemistry laboratory between April 2018 and April 2019.

The team analyzed 1,348 serum samples for serum HE4 using both the conventional manual enzyme immunometric-assay (EIA), and an automated chemiluminescent immunoassay (CLEIA) methods. Samples were analyzed using the HE4 EIA (Fujirebio, Gent, Belgium) and the Lumipulse G600II analyzer also from Fujirebio. The EIA is a solid phase non-competitive immunoassay using mouse monoclonal antibodies (MAb) 2H5 and 3D8 directed against different HE4 epitopes. The maximum detection limit is 900 pmol/L. The CLEIA uses a two-step sandwich immunoassay technique. The immunoreaction cartridges contain two monoclonal antibodies, MAb 2H5 and alkaline phosphatase (ALP)-labeled MAb 12A2. The maximum detection limit is 1,500 pmol/L.

The investigators demonstrated in their study a significant difference in serum HE4 values measured using CLEIA and conventional EIA. There was moderate agreement between the two methods, but CLEIA significantly overestimated HE4 values when compared to EIA, with a mean percentage bias of 16.25%. Identified biases of 7.2 pmol/L and 10 pmol/L, at the thresholds of 70 pmol/L and 140 pmol/L respectively, are likely to significantly impact clinical interpretation and decision making when using values measured by the CLEIA, highlighting the importance of assay-specific cut-offs for clinical application.

The authors concluded that the CLEIA significantly overestimates HE4 values compared to the EIA, suggesting that a common clinical decision limit may not be appropriate. The study was published in the August, 2021 issue of the journal Practical Laboratory Medicine.

Related Links:
Manchester Academic Health Science Centre
Fujirebio


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.